Biogen Inc (BIIB)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $37.46B
Last updated: Nov 17, 2026 at 11:04 AM ET
Biogen Inc (BIIB) Stock Forecast
Analysts expect Biogen (BIIB) to earn $12.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $10.57B. Of 36 analysts, 25 rate the stock Buy or Strong Buy, 10 Hold and 1 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $16.26.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 36 ratings average 2.22, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 69% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 11.1% |
| Buy | 21 | 58.3% |
| Hold | 10 | 27.8% |
| Sell | 1 | 2.8% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 36
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 29.8% and revenue estimates rise 2.0%.
- Fiscal year ending Dec 31, 2026
- $12.53
- EPS consensus, revenue $10.57B
- Fiscal year ending Dec 31, 2027
- $16.26
- EPS consensus, revenue $10.78B
- Next report
- Feb 4, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $12.53 | $12.22 to $13.07 | 33 | $10.57B | $10.28B to $11.40B | 34 |
| Dec 31, 2027 | $16.26 | $13.90 to $18.67 | 35 | $10.78B | $10.21B to $11.09B | 34 |
Quarterly Estimates
The EPS consensus rises from $2.81 for the quarter ending Dec 31, 2026 to $3.57 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.81 | $2.39 to $3.45 | 33 | $2.65B | $2.38B to $3.55B | 32 |
| Mar 31, 2027 | $3.57 | $2.93 to $4.18 | 13 | $2.61B | $2.37B to $2.73B | 12 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 12 | 12 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.7% from $12.44.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $12.53 | $12.53 | $12.43 | $12.49 | $12.44 | +0.7% |
| Fiscal year ending Dec 31, 2027 | $16.26 | $16.28 | $16.55 | $16.55 | $16.60 | -2.1% |
| Quarter ending Mar 31, 2027 | $3.57 | $3.55 | $3.65 | $3.65 | $3.65 | -2.2% |
Frequently Asked Questions About BIIB
What is the BIIB stock forecast?
Consensus analyst estimates put Biogen's EPS at $12.53 for the fiscal year ending Dec 31, 2026, on revenue of $10.57B. The consensus rating from 36 analysts is Buy.
How do analysts rate BIIB stock?
Of 36 analysts covering Biogen, 4 rate it Strong Buy, 21 Buy, 10 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from BIIB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $12.53, with estimates from $12.22 to $13.07 from 33 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $16.26, with estimates from $13.90 to $18.67 from 35 analysts.
What revenue do analysts expect from Biogen next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $10.57B, with estimates from $10.28B to $11.40B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $10.78B, with estimates from $10.21B to $11.09B.
How many analysts cover BIIB?
36 analysts rate Biogen stock, and 33 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BIIB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors